Ligand– tag –
-
Alcimed Analyzes Brain Drug Delivery Barriers and Breakthroughs: Receptor-Mediated Transcytosis and LIFU as Key Enablers
Alcimed France Overview Brain drug delivery is one of modern medicine's most complex challenges due to multiple physiological barriers, notably the blood-brain barrier (BBB), which severely restricts most therapeutic molecules from enter... -
Breaking the Blood-Brain Barrier: Nanoparticles Chart New Course for Neurodegenerative Therapies
Dove Medical Press New Zealand Overview The blood-brain barrier (BBB) prevents over 98% of small-molecule drugs and nearly all biologics from entering the brain, posing a major challenge for neurological therapies. Nanoparticles (NPs) of... -
Arrowhead’s Plozasiran Achieves Up to 81% Triglyceride Reduction in Severe Hypertriglyceridemia Phase 3, Pressuring Ionis
Fierce Biotech USA Overview Arrowhead Pharmaceuticals has reported robust Phase 3 SHASTA-3 and SHASTA-4 trial data for its siRNA therapeutic, plozasiran, in patients with severe hypertriglyceridemia (sHTG), putting pressure on competitor... -
Frontiers Review Highlights RNA-Based Drugs’ Transformative Role in Modern Medicine, Emphasizing siRNA, mRNA, and ASO Delivery Strategies
Frontiers Switzerland Overview A Frontiers review comprehensively outlines the evolution of RNA therapeutics into innovative medical approaches by directly targeting disease-related RNA molecules. The review highlights the mechanisms of ... -
siRNA Overcomes Gene Silencing Challenges with LNP and GalNAc Conjugation, Expanding Therapeutic Applications
Inside Therapeutics USA Overview Inside Therapeutics details how siRNA, while offering transformative gene silencing, is overcoming delivery challenges through lipid nanoparticles (LNP) and N-acetylgalactosamine (GalNAc) conjugation tech... -
Investor Focus: RNA Platform Success Hinges on Extrahepatic Delivery Capabilities Beyond the Liver
Bioprocess Online USA Overview Bioprocess Online highlights that a key question for investors evaluating RNA therapeutic platforms is the ability to effectively deliver RNA to diverse extrahepatic organs. While current successes often le... -
RNA Medicines Enter ‘Second Act’ Post-COVID-19, Focusing on Extrahepatic Delivery Beyond the Liver
European Biotechnology Magazine Germany Overview RNA therapeutics are entering a 'second act' after the success of mRNA vaccines during the COVID-19 pandemic, with a critical focus on developing effective delivery technologies to extrahe... -
Nanotechnology Revolutionizes Cancer Theranostics: Precision Targeting Achieved with Radioligand Therapy Integration
J Clin Oncol Ther / Scholars Literature International Overview This review highlights nanotechnology's role in enhancing theranostic efficacy in oncology, especially when combined with radioligand therapy. Nanoparticles like gold, iron o... -
BBB-Permeable Nanoparticles: A Novel Strategy for Breakthrough Neurodegenerative Disease Therapies
DovePress - International Journal of Nanomedicine UK Overview Research published in the 'International Journal of Nanomedicine' reports that the latest design of nanoparticles effectively crossing the blood-brain barrier (BBB) has brough... -
RNAi Therapeutics Advance in Metabolic Disease Treatment with Liver-Targeted DDS and Emerging Self-Delivery siRNAs
ResearchGate (Trends in Pharmacological Sciences) Unknown Overview This article discusses RNA interference (RNAi) as a therapeutic strategy for metabolic diseases, emphasizing its advantage in targeting virtually all genes. Despite deliv...
